35.172.223.251
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Retina

COVID-19 care delays linked with worse short-term outcomes in neovascular AMD

Posted on October 6, 2020

Delayed care due to the COVID-19 pandemic was associated with worse short-term outcomes in patients with neovascular age-related macular degeneration (AMD), according to a new study.

A total of 100 patients (112 eyes) with neovascular AMD who were evaluated between March 9, 2020 (during the Italian COVID-19 quarantine) and June 12, 2020 (immediately after the quarantine), were included. A complete ophthalmologic evaluation was performed at the initial visit and compared to findings from the 2 preceding visits.

The time interval from the study visit to the first preceding visit was 110.7 ± 37.5 days; from the first preceding visit to the second preceding visit, the time interval was 80.8 ± 39.7 days.

At the study visit, best-corrected visual acuity (BCVA) was statistically worse compared with the immediately preceding. In approximately 81% of eye there was evidence of exudative disease activity at the first study visit, whereas only 69% of eyes exhibited signs of exudation at the preceding visit. Between the 2 preceding visits there were no differences in BCVA and optical coherence tomography findings.

A multiple regression analysis showed that the difference in BCVA between the study visit and the first preceding visit was significantly associated with the interval time within these 2 visits (P =0.026).

Reference
Borrrelli E, Grosso D, Vella G, et al. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020;https://doi.org/10.1007/s00417-020-04955-7.

-Advertisement-
Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-